Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...
Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
7 Jun 2022
Biomarker analysis of the NeoALTTO trial provides oncofertility insight for youn...
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2022
Pembrolizumab demonstrates clinically meaningful improvement in distant metastas...
Dr Georgina Long - The University of Sydney, Sydney, Australia
Pembrolizumab demonstrates clinically meaningful improvement in distant metastasis-free survival in patients with melanoma ( Dr Georgina Long - The University of Sydney, Sydney, Australia )
6 Jun 2022
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer wi...
Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San ...
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients ( Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
6 Jun 2022
ASCO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ASCO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2022
Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of...
Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands
Neoadjuvant ipilimumab and nivolumab  immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )
6 Jun 2022
Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA ...
Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA
Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody ( Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA )
6 Jun 2022
CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper resp...
Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain
CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib ( Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain )
6 Jun 2022
Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer P...
Dr Pamela Kunz - Yale Cancer Center, New Haven, USA
Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone ( Dr Pamela Kunz - Yale Cancer Center, New Haven, USA )
6 Jun 2022
ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal strom...
Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain
ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour ( Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
6 Jun 2022
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-ty...
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )
6 Jun 2022
Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )
6 Jun 2022